Cell Innovation Partners was launched in 2014 with the aim of creating next generation biotechnology businesses. In recent years universities and research institutes around the world have accelerated stem cell, including iPS cell, and regenerative medicine research. However, there exists a lack of funds required to translate the results of this research into a meaningful application into the field of regenerative medicine. Cell Innovation Partners supports the realization of future biotechnology business through the provision of risk money to both domestic and overseas stem cell/ regenerative medicine venture companies.
Cell Innovation Partners has two distinct characteristics compared to average venture capitals investing in biotechnology companies. First, we focus on stem cell/ regenerative medicine venture companies. While average venture capitals target the overall life sciences area, Cell Innovation Partners specifically targets venture companies in the stem cell and regenerative medicine fields and invests in those companies utilizing its deep understanding of the industries, businesses and technologies. Second, we look to contribute to the business development of the companies we invest in. Leveraging our experiences in successful business development as a biotech venture company, our R&D expertise in the stem cell and regenerative medicine fields, the business network of ReproCell, expertise regarding capital policies and the financial network of the Shinsei Bank Group, Cell Innovation Partners supports the growth of companies both in business development as well as finance.
|Name||Cell Innovation Partners Limited|
|Registered Location||Cayman Island|
|Managing Fund||Cell Innovation Partners, L.P. （Fund Size:JPY 900 million）|
From Shin-Yokohama Station (JR):
10 minute walk from Shin-Yokohama North Gate exit
From Tokyo Station (JR):
7 minutes’ walk from Nihombashi Exit
From Mitsukoshimae Station (Tokyo Metro):
1 minute’s walk from A9 Exit (Ginza Line or Hanzomon Line)